All In Biotech

Drug Trial Radar · NCT04755543

A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms

A Phase I Study of Safety and Pharmacokinetics of LP002 (a Humanized Monoclonal Antibody Targeting PD-L1) in Patients With Malignant Digestive System Neoplasms

Last checked: Nov 19, 2026Latest source record: Feb 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

94

Planned (sponsor's estimate)

Start

Jun 17, 2019

Primary completion

Jun 30, 2021

Study completion Jun 30, 2022

Sponsor

Sponsor type
Industry
First posted
Feb 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

LP002 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. In this study, the safety, pharmacokinetics and preliminary efficacy of LP002 for the treatment of malignant digestive system neoplasms will be evaluated.

Conditions

  • Digestive System Neoplasms

Interventions

  • LP002Drug

    600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W).

  • CisplatinDrug

    50mg/m2 IV on Day 1, Q2W

  • FluorouracilDrug

    2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W

  • OH2 oncolytic virusBiological

    106 or 107 or 108 CCID50/mL by intra-tumoral injection, Q2W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Time frame: up to approximately 24 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Henan Cancer Hospital & Insititute

    Zhengzhou, Henan, China · Recruiting

  • Hubei Cancer Hospital & Insititute

    Wuhan, Hubei, China · Recruiting

  • Liaoning Cancer Hospital & Insititute

    Shenyang, Liaoning, China · Recruiting

  • The First Affiliated Hospital. Zhejiang University School Of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • The First Affiliated Hospital. Zhejiang University School Of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.